Q/C TECHNOLOGIES, INC.
Close on Oct 19, 2026
- Market cap
- $4.12M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2018 Ended Sep 30, 2018 | Nov 15, 2018 | Before market open | – | – | – |
Press releases
Announcements Q/C Technologies filed with the SEC
Q/C Technologies Names Yossef Ehrlichman Chief Technology
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS”
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum
Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Pharmaceuticals Announces Closing of $7 Million Private Placement
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
Material agreement · Agreement terminated · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance
Material agreement · Agreement terminated · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market
Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief
Material agreement · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture
Regulation FD disclosure · EX-99.1 to Form 8-K
Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1 ®
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Phase 2 Trial Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports Statistically Significant Positive Topline
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Pharmaceuticals ® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1 ®
Regulation FD disclosure · EX-99.1 to Form 8-K
Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces U.S. Drug Enforcement Administration (DEA) Determines
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals ® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces $15 Million Offering with Existing Investors
Material agreement · Other events · EX-99.1 to Form 8-K
Pharmaceuticals ® to Present Data on
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals ® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1 ® at the 2022 British
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals ® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1 ® as a Therapy
Regulation FD disclosure · EX-99.1 to Form 8-K
PHARMACEUTICALS RECEIVES GRANT FROM EUROPEAN
Regulation FD disclosure · EX-99.1 to Form 8-K
Showing MyMD Pharmaceuticals’ MYMD-1 ® May Extend Life and Improve Health Published in the Journal of Gerontology:
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals ® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 ® as a Therapy for Delaying Aging
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Advances Phase 2 Multi-Center Clinical
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan
Regulation FD disclosure · EX-99.1 to Form 8-K